BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 24454709)

  • 21. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
    Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
    Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor.
    Zhuang W; Zhang W; Xie L; Wang L; Li Y; Wang Z; Zhang A; Qiu H; Feng J; Zhang B; Hu Y
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies.
    Osgood AO; Roy SJS; Koo D; Gu R; Chatterjee A
    Bioconjug Chem; 2024 Apr; 35(4):457-464. PubMed ID: 38548654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates.
    Petersen ME; Brant MG; Lasalle M; Das S; Duan R; Wong J; Ding T; Wu KJ; Siddappa D; Fang C; Zhang W; Wu AML; Hirkala-Schaefer T; Garnett GAE; Fung V; Yang L; Hernandez Rojas A; Lawn SO; Barnscher SD; Rich JR; Colombo R
    Mol Cancer Ther; 2024 May; 23(5):606-618. PubMed ID: 38354417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.
    Yamazaki CM; Yamaguchi A; Anami Y; Xiong W; Otani Y; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Nat Commun; 2021 Jun; 12(1):3528. PubMed ID: 34112795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
    Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.
    Xu K; Han J; Yang L; Cao L; Li S; Hong Z
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
    Barok M; Puhka M; Yazdi N; Joensuu H
    J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload.
    Jeon JH; Woo Kim S; Kim YJ; Park JW; Eun Moon J; Beom Lee Y; Yu H; Lee GH; Jin SH; Jeong JH
    Bioorg Chem; 2024 May; 149():107504. PubMed ID: 38850783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates.
    Johann F; Wöll S; Winzer M; Gieseler H
    J Pharm Sci; 2024 May; 113(5):1265-1274. PubMed ID: 38070776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific Antibody-Nitric Oxide Conjugate HN02 Possesses Improved Antineoplastic and Safety Properties.
    Cheng T; Xie J; Yuan X; Guo M; Wu J; Wang M; Huang Z; Zhang J
    J Immunother; 2024 Jun; 47(5):149-159. PubMed ID: 38557756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
    J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.